Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Jemperli Injection
Manufacturer/Marketed By : GLAXO SMITHKLINE PHARMACEUTICALS LTD
$4160.28 $3536.24
Jemperli Injection is a prescription medicine used in the treatment of certain advanced or recurrent cancers. It belongs to the class of immune checkpoint inhibitors that target the programmed death...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
DOSTARLIMAB
Active Pharmaceutical Ingredient
Jemperli Injection
$4,160.28
$3,536.24
Jemperli Injection is a prescription medicine used in the treatment of certain advanced or recurrent cancers. It belongs to the class of immune checkpoint inhibitors that target the programmed death receptor-1 (PD-1) pathway. By blocking PD-1, Jemperli Injection restores the ability of the immune system to detect and attack cancer cells. It is given as an intravenous (IV) infusion, typically every 3–6 weeks, under medical supervision. Jemperli Injection has shown particular benefit in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumours, which rely on faulty DNA repair mechanisms. Regular monitoring of liver function, thyroid levels, and immune-related side effects is necessary. As an immunotherapy, it may cause the immune system to attack healthy tissues (immune-related adverse events). It should not be used during pregnancy or breastfeeding, and patients with autoimmune conditions or organ transplants must inform their doctor before starting therapy. Jemperli injection price varies by retailer and location.
Active Pharmaceutical Ingredient
Uses
• Treatment of adult patients with recurrent or advanced dMMR/MSI-H endometrial cancer that has progressed on or after prior therapy and who are not candidates for curative surgery or radiation.
• Treatment of adult patients with dMMR/MSI-H recurrent or advanced solid tumours (including colorectal cancer) that have progressed on or after prior treatment and have no satisfactory alternative options.
• Investigated in clinical trials for ovarian cancer, endometrial cancer (first-line), and other advanced solid tumours.
Benefits
Jemperli Injection is used in the treatment of certain types of cancer, particularly endometrial cancer. It works by enhancing the body’s immune system to recognize and attack cancer cells more effectively. This medicine blocks specific proteins that prevent immune cells from detecting cancer, allowing the immune system to respond more strongly against tumor cells. By boosting the body’s natural defenses, it helps slow down or stop the progression of the disease. It may also help reduce tumor size and improve symptoms, supporting better treatment outcomes and overall quality of life.
Side Effects
Serious (immune-related):
Most Common Side Effects
• Fatigue
• Nausea
• Diarrhoea or constipation
• Loss of appetite
• Anemia
• Cough
• Rash or itching
• Muscle/joint pain
Common Side Effects
• Pneumonitis (lung inflammation: cough, chest pain, shortness of breath)
• Hepatitis (jaundice, dark urine, abdominal pain)
• Colitis (diarrhoea, bloody stools, abdominal pain)
• Endocrinopathies (thyroid, pituitary, adrenal problems causing fatigue, weight change, mood changes)
• Severe skin reactions (rash, blistering, peeling)
• Infusion reactions (fever, chills, dizziness, shortness of breath)
How To Use
Administered as an intravenous (IV) infusion over 30 minutes by a healthcare provider.
Safety Advice
• Pregnancy: It is recommended to avoid Jemperli Injection during pregnancy, as it may harm the developing fetus. If you are pregnant, planning to become pregnant, or suspect pregnancy, consult your doctor before starting treatment. The doctor will assess the potential risks and benefits.
• Breast Feeding: It is unknown whether Jemperli Injection passes into breast milk. Consult your doctor before taking this medicine while breastfeeding. The doctor may prescribe it only if the expected benefits outweigh the potential risks.
• Lungs: Immune checkpoint inhibitors like Jemperli Injection may cause inflammation in the lungs (pneumonitis). Consult your doctor if you have a history of lung disease or experience breathing difficulties before starting this treatment.
• Liver: Jemperli Injection may cause immune-mediated hepatitis or elevate liver enzymes. Inform your healthcare provider if you have liver disease or abnormal liver function before starting treatment.
• Alcohol: There is limited information on alcohol use with Jemperli Injection , but combining alcohol may worsen fatigue or affect liver function. Please consult your doctor before consuming alcohol during treatment.
• Driving: Jemperli Injection may cause fatigue or dizziness in some patients. It is advised to avoid driving or operating heavy machinery until you understand how the medicine affects you.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.